This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BTT-1023

Biotie Therapies Corp.

Drug Names(s): BTT1023, VAP-1 Antibody

Description: BTT-1023 is a fully human monoclonal antibody targeted against the Vascular Adhesion Protein-1 (VAP-1) receptor. Inhibiting VAP-1 is thought to reduce inflammation by regulating the migration of leukocytes, or white blood cells, to inflamed tissues.

Deal Structure: Biotie and Roche
In November 2006, Biotie signed an option agreement with Roche for the antibody program targeting VAP-1. Under the terms of the agreement, Roche has paid an option initiation fee of EUR 5 million, which grants Roche an exclusive option right to an exclusive, worldwide license agreement for Biotie's fully human antibody targeting VAP-1, excluding Japan, Taiwan, Singapore, New Zealand, and Australia. The initial option right will end upon completion of Phase I trials. Roche may extend the option right to later development points by paying additional fees. Biotie will retain all rights to the program until a license is granted to Roche.

In April 2010, Biotie announced that Roche has decided not to exercise its opt-in right for BTT-1023.

Biotie and Seikagaku
Seikagaku Corporation has licensed the rights for BTT-1023 in Japan, Taiwan, Singapore, New Zealand, and Australia and could pay up to USD 16.7 million in milestone payments plus...See full deal structure in Biomedtracker


BTT-1023 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug